Direct to Bladder Therapies

About UroPharma

• UroPharma has patented and developed the world’s first licensed ‘direct to bladder’ drug delivery system, that will be in the market by early 2023.

• This overcomes clinical limitations and significant harms caused by the oral delivery of drugs intended for bladder therapy.

• The design incorporates safety features intended to reduce costs associated with treating catheter acquired urinary tract infections caused by antibiotic resistance.

• Urinary tract infections represent a substantial cost burden to the healthcare system and catheters are the biggest contributors to this global problem.

• Urinary Tract Infections, Overactive Bladder, incontinence, Multiple Sclerosis and Spinal Cord Injury are a substantial reducer of quality of life with millions of people.

We’ll be very interested in your feedback and questions

See the Market size